AST-1306 CAS NO.897383-62-9

 

We have been providing over 1000 products including molecular targeted anticancer drugs, cell signaling pathway

 

inhibitors, pharmaceutical intermediates, and heterocyclic compounds, and quality services including custom

 

synthesis, transfer of new drug patent and technology, technical cooperation, and process optimization.

 

 

Jinan Trio PharmaTech was founded by a core group of top overseas pharmaceutical chemists, Medical scientists and

 

business management experts, and is an enterprise of science and technology supported by the "Attracting High-

 

Level Talent Scheme" of Jinan government.

 

 

Jinan Trio PharmaTech Co., Ltd. 

 

Year Establishment: 2008

 

Location: We are located at one of the largest National Technical Integrated Drug Discovery Platforms in the High-Tech Zone of Jinan City

 

Our company was founded by a core group of top overseas pharmaceutical chemists, medical scientists business

management experts

 

We have built up solid cooperation with over twenty oversea companies over one hundred domestic companies

since the foundation

 

 

 

 

 

 

 

 

Specifications:

 

 

Name  N-[4-[[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-propenamide

 

Synonyms  N-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]quinazolin-6-yl]acrylamide; ALS 1306; AST 1306; AST 6

 

Molecular Formula  C₂₄H₁₈ClFN₄O₂

 

Molecular Weight  448.88

 

CAS Registry Number  897383-62-9

 

Density  1.395

 

Boiling point  655 ºC

 

Flash point  350 ºC

  
 

 

Applications:

 

 

 

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB4 with IC50 of 0.5 nM and 0.8 nM, respectively.